about
Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy.Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice."Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer.KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease.Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome."Palliative" or "Supportive": Is It Just a Matter of Word?Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary reportWeekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practiceA multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableSafe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on DialysisLooking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory EvaluationWhere are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives.Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 studyThe PERSONS score for symptoms assessment in simultaneous care setting: A pilot studyTimed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimenEvaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyPrognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabValidation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patientsFamily history of cancer and DNA damage response genes: Two sides of the same coin?The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practiceA systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patientsImmune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinomaEarly fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practiceImpact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter studyFirst-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experienceWhat cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudesWeight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre studyCancer Care After Natural Disaster: Different Countries, Similar ProblemsSingle-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapyClinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse StudyClinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancerCorrelations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC PatientsOsimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudesThe PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settingsNotch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challengesWeighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life studyImmune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With NivolumabThe Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need TrialThe Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
P50
Q41274080-947BF094-9904-4D16-A037-5A9C2DF47F60Q45785941-33FD5171-DD6F-4E14-8DEC-165CD1EC2285Q48126555-2FBF8FFF-56F8-4240-8398-82FE6A053068Q48207420-6E10674D-9BF3-4650-9A6E-2AFA55EC10ACQ50152459-4C5A9AE1-BE16-4B90-BBD5-873D2F257C81Q55076131-7842BCD2-3652-473E-B83B-6545731FD567Q58082411-5906DDF1-5B13-4361-8F5A-37D260072E6AQ61807868-E70F4E43-AE78-4671-B585-E204B70EF006Q64056233-0DE8AF31-A917-47FC-BC60-8636BB41B736Q64095960-581A738E-6F3C-4186-8090-523A96167D16Q64226459-C878626B-8BA9-4E02-BA4E-1A67FE94D46EQ64229668-82132926-77FA-4975-96A2-D27925F91274Q64957596-5A958391-442F-4350-B500-920D08A7C2A6Q88122246-4C69988C-4348-4D01-8DF7-DA26FCFC6761Q88786931-48C69958-3B91-49E8-9BA5-F03719E84350Q89099856-BCCD2875-E907-4083-BC30-31550BC15C41Q89457680-6725D283-1408-4982-AB53-AA11C3FE2EF9Q89500693-47641157-F8AD-4298-8735-8F0949DD3D51Q90101067-89B06CC6-996F-4493-99C3-25D167C66081Q90399811-25676E6D-E228-490F-9D10-7C799D9C19B6Q90465793-1DB1BBE1-3FB4-4B94-9E5B-4C1FCCF3D67FQ91284700-6FBB8ACB-030C-45CC-AAB1-E754EEB8609AQ91287318-E13C5BB3-6192-4BC5-9173-BB07E2E9DD11Q91294145-561CEDBB-0E13-48FE-9CF2-63E6DB763B83Q91427527-8034C412-20C0-4B25-BB42-918F5E68D600Q91661022-4FE7E433-28B9-4855-A4A1-062A9279D0BAQ91664175-C8A12531-AAFC-4650-9A20-4CF3A3E3EA2AQ91680396-77C3B93D-320F-48CA-96FB-EBB4ABA3350AQ91706763-668F0328-6EA8-4954-BC49-132203F45AB8Q91799279-7A545A3B-906C-4F12-95D9-81519BE0949BQ91843400-649C9832-B124-4ABA-BAA1-7D9D47E45676Q92097537-30A1F0E3-9C35-43F7-BA59-F6E5A2EAC990Q92455613-0DF68193-CEAC-4AD8-A74B-593204AC7185Q92490753-2D7FEE47-1028-4DFB-8F69-EF7AEA92F401Q92755165-BCED820A-D2A0-4A70-912B-7AEB80F314E6Q92991247-C4B51F3E-1FA7-4546-A4B3-AF02D0DDCC82Q93039807-691B075B-8F9E-43B2-9FB4-2AC22762D66FQ93141026-45280AB9-CEE5-434A-9B74-DA14E55E1A00Q93186117-45DD479B-317F-4A2E-A200-FB70DC01DFA3Q94470762-3F1ABC43-B146-403C-B8CA-7AEBE0E00C57
P50
description
researcher ORCID ID = 0000-0002-1209-5735
@en
name
Alessio Cortellini
@ast
Alessio Cortellini
@en
Alessio Cortellini
@es
Alessio Cortellini
@nl
type
label
Alessio Cortellini
@ast
Alessio Cortellini
@en
Alessio Cortellini
@es
Alessio Cortellini
@nl
prefLabel
Alessio Cortellini
@ast
Alessio Cortellini
@en
Alessio Cortellini
@es
Alessio Cortellini
@nl
P1153
57195202998
P31
P496
0000-0002-1209-5735